What policy makers need to know about COVID-19 protective immunity.

Altmann, Daniel M; Douek, Daniel C; Boyton, Rosemary J

Altmann, Daniel M; Douek, Daniel C; Boyton, Rosemary J.

Altmann DM; Department of Immunology and Inflammation, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK. Electronic address: d.altmann@ic.ac.uk.
Douek DC; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Boyton RJ; Department of Infectious Diseases, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK; Lung Division, Royal Brompton & Harefield NHS Foundation Trust, London, UK.

Lancet ; 395(10236): 1527-1529, 2020 05 16.

Article in English | MEDLINE | ID: covidwho-125145

Subject(s)

Administrative Personnel; Coronavirus Infections/immunology; Coronavirus Infections/prevention & control; Immunity, Herd; Pandemics/prevention & control; Pneumonia, Viral/immunology; Pneumonia, Viral/prevention & control; Antibodies, Viral/blood; Betacoronavirus; COVID-19; COVID-19 Testing; Clinical Laboratory Techniques; Coronavirus Infections/diagnosis; Humans; Mass Vaccination; Pneumonia, Viral/diagnosis; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Administrative Personnel / Coronavirus Infections / Immunity, Herd / Pandemics Type of study: Diagnostic study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Lancet Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google